Sofwave Medical reported a strong first quarter for fiscal 2026, with revenue rising 46% year-over-year to $24.4 million and net income turning positive at $1.3 million under IFRS. The company saw a 56% increase in recurring usage fees, reflecting growing adoption of its non-invasive aesthetic treatments, especially among patients using GLP-1 therapies. Gross margin remained robust at 75%, and operating expenses as a percentage of revenue decreased, signaling improved efficiency. With nearly 2,900 systems sold and over 865,000 treatments performed, Sofwave is capitalizing on rising demand for regenerative aesthetic solutions and plans to continue expanding its global market presence.
The global pharmaceutical surfactants market, valued at $4.5 billion in 2025, is projected to grow to $6.93 billion by 2035 at a CAGR of 4.42%. Growth is fueled by increasing use in drug formulation to enhance solubility, stability, and bioavailabili...
Noble Corporation reported weaker-than-expected revenue and earnings per share for Q2 2026 due to vessel suspensions and contract completions. Despite lowering its full-year 2026 guidance, the company maintains a strong backlog of $6.8 billion and ri...
Bitcoin fell more than 3% to around $63,494, hitting a 10-day low as tech stocks tied to AI plunged, notably South Korea's KOSPI dropping over 10%. This sell-off spread to digital assets, with Ethereum, Solana, and XRP also declining. Market uncertai...
CoinMarketCap's Altcoin Season Index increased to 53, indicating a slight improvement in altcoin performance relative to Bitcoin. However, this level remains below the 75 threshold that signals a full altcoin season, keeping the market in a neutral s...
Unilever reported its strongest quarterly volume growth in more than ten years, with underlying sales rising 5.8% in Q2, surpassing analyst expectations. Sales volumes increased 5.5%, and revenue reached €13.05 billion, beating forecasts. The company...
